


Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application.

Claims

Claim 1 (currently amended): A compound of formula (I) or a salt, solvate or pro-drug or an *in vivo* hydrolysable ester or amide thereof,



(I)

wherein:

Ring A is pyridin-2-yl or thiazol-2-yl; wherein said pyridin-2-yl or thiazol-2-yl is optionally substituted on carbon by one or more groups selected from R⁴;

one of R¹ and R² is hydrogen and the other is hydrogen or C₁₋₄alkyl; wherein R¹ and R² are optionally substituted on carbon by one or more groups selected from R⁵;

R³ is selected from C₁₋₄alkyl, C₁₋₄alkoxy, carbocyclyl, heterocyclyl, carbocyclyloxy and heterocyclyloxy; wherein R³ is optionally substituted on carbon by one or more groups selected from R⁶; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C₁₋₄alkyl;

R⁴ is selected from halo, carboxy and C₁₋₄alkyl;

R⁵ and R⁶ are independently selected from halo, C₁₋₄alkyl, C₁₋₄alkoxy, N-(C₁₋₄alkyl)amino, N,N-(C₁₋₄alkyl)₂amino, carbocyclyl, heterocyclyl, carbocyclyloxy, heterocyclyloxy and carbocyclylidенyl; wherein R⁵ and R⁶ are independently optionally substituted on carbon by one or more R⁷; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C₁₋₄alkyl;

R⁷ is selected from halo, carboxy, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and N-methyl-N-ethylamino.

Claim 2 (currently amended): The compound according to Claim 1 or a salt, ~~solvate or pro-drug or an *in vivo* hydrolysable ester or amide thereof~~, wherein Ring A is unsubstituted or is substituted by carboxy.

Claim 3 (currently amended): The compound according to Claim 2 or a salt, ~~solvate or pro-drug or an *in vivo* hydrolysable ester or amide thereof~~, wherein one of R¹ and R² is hydrogen and the other is hydrogen or C₁₋₄alkyl.

Claim 4 (currently amended): The compound according to Claim 1 or a salt, ~~solvate or pro-drug or an *in vivo* hydrolysable ester or amide thereof~~, wherein R³ is selected from C₁₋₄alkoxy; wherein R³ is optionally substituted on carbon by one or more groups selected from R⁶.

Claim 5 (currently amended): The compound according to Claim 1 or a salt, ~~solvate or pro-drug or an *in vivo* hydrolysable ester or amide thereof~~, wherein R³ is selected from 2-fluorobenzyloxy, 5-methylisoxazol-3-ylmethoxy and 2-thien-3-yethoxy.

Claim 6 (currently amended): A compound according to Claim 1 or a salt, ~~solvate or pro-drug or an *in vivo* hydrolysable ester or amide thereof~~ selected from:

2-methyl-4-isobutoxy-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

2-methyl-4-(2-fluorophenylmethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

2-methyl-4-isobutoxy-6-[N-(5-carboxythiazol-2-yl)carbamoyl]benzofuran;

2-methyl-4-(5-methylisoxazol-3-ylmethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

4-(2-fluorophenylmethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

4-(5-methylisoxazol-3-ylmethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;


2-methyl-4-(thien-2-yethoxy)-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran; and

2-methyl-4-isobutoxy-6-[N-(thiazol-2-yl)carbamoyl]benzofuran.

Claim 7 (currently amended): The pharmaceutical composition comprising a compound according to any one of Claims 1 to 6, or a salt, ~~pro-drug or solvate or an in vivo hydrolysable ester or amide~~ thereof, together with a pharmaceutically acceptable diluent or carrier.

Claim 8 (currently amended): The method of treating a disease mediated through glucokinase, comprising administering an effective amount of a compound according to any one of Claims 1 to 6 or a salt, ~~pro-drug or solvate or an in vivo hydrolysable ester or amide~~ thereof.

Claim 9 (currently amended and withdrawn): A method for preparing a compound of formula (I) or a salt, ~~solvate or pro-drug or an in vivo hydrolysable ester or amide~~ thereof:



(I)

wherein:

Ring A is pyridin-2-yl or thiazol-2-yl; wherein said pyridin-2-yl or thiazol-2-yl is optionally substituted on carbon by one or more groups selected from R⁴; one of R¹ and R² is hydrogen and the other is hydrogen or C₁₋₄alkyl; wherein R¹ and R² are optionally substituted on carbon by one or more groups selected from R⁵; R³ is selected from C₁₋₄alkyl, C₁₋₄alkoxy, carbocyclyl, heterocyclyl, carbocyclyloxy and heterocyclyloxy; wherein R³ is optionally substituted on carbon by one or more groups selected from R⁶; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C₁₋₄alkyl;

R⁴ is selected from halo, carboxy and C₁₋₄alkyl;


R⁵ and R⁶ are independently selected from halo, C₁₋₄alkyl, C₁₋₄alkoxy, N-(C₁₋₄alkyl)amino, N,N-(C₁₋₄alkyl)₂amino, carbocyclyl, heterocyclyl, carbocyclyloxy, heterocyclyloxy and

carbocyclylidenyl; wherein R⁵ and R⁶ are independently optionally substituted on carbon by one or more R⁷; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C₁₋₄alkyl;

R⁷ is selected from halo, carboxy, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and N-methyl-N-ethylamino;


wherein the method comprises:

Process 1): reacting an acid of formula (II):




(II)

or an activated derivative thereof, with a compound of formula (III); or



(III)

Process 2) for compounds of formula (I) wherein R⁴ is carboxy; deprotecting a compound of formula (III):



(III)


wherein R^x-OC(O) is an ester group and R^x is selected from C₁₋₆ alkyl and benzyl;
and optionally:

i) converting a compound of the formula (I) into another compound of the formula (I); and/or

ii) removing any protecting groups; and/or

iii) forming a salt, solvate or pro-drug or an *in vivo* hydrolysable ester or amide thereof.

Claim 10 (withdrawn): A compound of formula (III):



(III)

wherein:

R^x-OC(O) is an ester group and **R^x** is selected from C₁₋₆ alkyl and benzyl;

Ring A is pyridin-2-yl or thiazol-2-yl; wherein said pyridin-2-yl or thiazol-2-yl is optionally substituted on carbon by one or more groups selected from R⁴;

one of **R¹** and **R²** is hydrogen and the other is hydrogen or C₁₋₄alkyl; wherein R¹ and R² are optionally substituted on carbon by one or more groups selected from R⁵;

R³ is selected from C₁₋₄alkyl, C₁₋₄alkoxy, carbocyclyl, heterocyclyl, carbocyclyloxy and heterocyclyloxy; wherein R³ is optionally substituted on carbon by one or more groups selected from R⁶; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C₁₋₄alkyl;

R⁴ is selected from halo, carboxy and C₁₋₄alkyl;

R⁵ and **R⁶** are independently selected from halo, C₁₋₄alkyl, C₁₋₄alkoxy, N-(C₁₋₄alkyl)amino,

N,N-(C₁₋₄alkyl)₂amino, carbocyclyl, heterocyclyl, carbocyclyloxy, heterocyclyloxy and carbocyclylidienyl; wherein R⁵ and R⁶ are independently optionally substituted on carbon by one or more R⁷; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C₁₋₄alkyl;

R⁷ is selected from halo, carboxy, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and N-methyl-N-ethylamino.

Claim 11 (withdrawn): The method of claim 9, wherein \mathbf{R}^x is selected from methyl and ethyl.

Claim 12 (withdrawn): The compound of claim 10, wherein \mathbf{R}^x is selected from methyl and ethyl.